Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × lanreotide × Endocrine × Clear all

Phase

Status

Sponsor Class

OTHER 12 INDUSTRY 7 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1 Endocrine 1

Conditions

Serotonin Syndrome 1 Carcinoid Heart Disease 1

Interventions

Octreotide 2 Ifosfamide 2 Filgrastim 2 Doxorubicin 2 vatalanib 1 vandetanib 1 tumor necrosis factor-alpha, CNGRC fusion protein, human 1 telotristat ethyl 1 motesanib diphosphate 1 mercaptoundecahydrododecaborate 1 lanreotide 1 batifiban 1 Temozolomide 1 Suramin 1 Radiotherapy 1 Hydrocortisone 1 Gene Expression Profiling 1 Everolimus 1 Etoposide 1 Docetaxel 1 DNA Methylation 1 Cyclophosphamide 1 Cisplatin 1 Chemotherapy, Adjuvant 1 Carboplatin 1 Capecitabine 1 Biological Therapy 1 Base Sequence 1 Amplified Fragment Length Polymorphism Analysis 1 4-boronophenylalanine-fructose 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡